Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) a biopharmaceutical company that engages in discovering, developing, and commercializing novel drugs that target G protein-coupled receptors in the therapeutic areas of cardiovascular, central nervous system ...

Boston, MA, 06/17/2013 (nysepost) - The share prices of Arena Pharmaceuticals, Inc (NASDAQ:ARNA) had declined by 6.71 percent to close at $7.88 per share for the end of last trading session on Friday.

Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) and VIVUS, Inc. (NASDAQ:VVUS) both make an anti-obesity product that is on the market.

Federal Home Loan Mortgage Corp(OTC:FMCC ) shares is trading at $1.39. The company on June 13 released the results of its Primary Mortgage Market Survey� (PMMS�), showing fixed mortgage rates climbing higher amid a solid employment report for ...

The consumer watchdogs are it again and this time their target is Arena Pharmaceuticals (ARNA) and Belviq, its anti-obesity drug.

Shares of Arena Pharmaceuticals, Inc (NASDAQ:ARNA) tumbled over 6% on Friday, as Consumer Reports recommends people skip the firm's new weight-loss medicine, Belviq.

SAN DIEGO, June 14, 2013 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that the company is scheduled to present a corporate overview at the 2013 Wells Fargo Securities Healthcare Conference on Wednesday, June 19, ...

The long anticipated launch of Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) anti-obesity drug is upon us. On Friday, June 7th, Arena and marketing partner Eisai Co.

Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) was in 13 hedge funds' portfolio at the end of the first quarter of 2013.

Shares of Arena Pharmaceuticals, Inc (NASDAQ:ARNA) tumbled over 6%, as Consumer Reports recommends people skip the firm's new weight-loss medicine, Belviq.